Adverse event costs of systemic therapies for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy and biologics in the US
Journal of Comparative Effectiveness Research · 2024
DOI: 10.57264/cer-2024-0084 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Comparative Effectiveness Research, 2024. Verfasst von Victoria Federico Paly und 5 weiteren Autor:innen. Beteiligte Einrichtung: Global Pricing, Value & Access; Global Health Economics & US HEOR - Oncology, Takeda Pharmaceuticals America, Inc., Lexington, MA 02421, USA. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Pyridines, Thymine, Trifluridine. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Aim
The objective of this study was to compare adverse event (AE) management costs for fruquintinib, regorafenib, trifluridine/tipiracil (T/T) and trifluridine/tipiracil+bevacizumab (T/T+bev) for patients with metastatic colorectal cancer (mCRC) previously treated with at least two prior lines of therapy from the US commercial and Medicare payer perspectives. Materials & methods: A cost-consequence model was developed to calculate the per-patient and per-patient-per-month (PPPM) AE costs using rates of grade 3/4 AEs with incidence ≥5% in clinical trials, event-specific management costs and duration treatment. Anchored comparisons of AE costs were calculated using a difference-in-differences approach with best supportive care (BSC) as a common reference. AE rates and treatment duration were obtained from clinical trials: FRESCO and FRESCO-2 (fruquintinib), RECOURSE (T/T), CORRECT (regorafenib) and SUNLIGHT (T/T, T/T+bev). AE management costs for the commercial and Medicare perspectives were obtained from publicly available sources.
Results
From the commercial perspective, the AE costs (presented as per-patient, PPPM) were: $4015, $1091 for fruquintinib (FRESCO); $4253, $1390 for fruquintinib (FRESCO-2); $17,110, $11,104 for T/T (RECOURSE); $9851, $4691 for T/T (SUNLIGHT); $8199, $4823 for regorafenib; and $11,620, $2324 for T/T+bev. These results were consistent in anchored comparisons: the difference-in-difference for fruquintinib based on FRESCO was -$1929 versus regorafenib and -$11,427 versus T/T; for fruquintinib based on FRESCO-2 was -$2257 versus regorafenib and -$11,756 versus T/T. Across all analyses, results were consistent from the Medicare perspective.
Conclusion
Fruquintinib was associated with lower AE management costs compared with regorafenib, T/T and T/T+bev for patients with previously treated mCRC. This evidence has direct implications for treatment, formulary and pathways decision-making in this patient population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Global Pricing, Value & Access; Global Health Economics & US HEOR - Oncology, Takeda Pharmaceuticals America, Inc., Lexington, MA 02421, USA.
- Department of Gastrointestinal Medical Oncology, MD Anderson Cancer Center, Houston, TX 77030, USA.
- Department of Hematology Oncology, Mayo Clinic, Rochester, MN 55905, USA.
- Medical Oncology, Mayo Clinic, Phoenix, AZ 85054, USA.
- US Medical Affairs - Oncology, Takeda Pharmaceuticals USA, Inc., Lexington, MA 02421, USA.
ORCID-Profile: Victoria Federico Paly, Luis Hernandez
Zitieren
APA
Paly, V. F., Dasari, A., Hubbard, J., Bekaii-Saab, T., Padukkavidana, T., & Hernandez, L. (2024). Adverse event costs of systemic therapies for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy and biologics in the US. Journal of Comparative Effectiveness Research. https://doi.org/10.57264/cer-2024-0084
Vancouver
Paly VF, Dasari A, Hubbard J, Bekaii-Saab T, Padukkavidana T, Hernandez L. Adverse event costs of systemic therapies for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy and biologics in the US. Journal of Comparative Effectiveness Research. 2024. doi:10.57264/cer-2024-0084
BibTeX
@article{Paly2024,
author = {Paly, Victoria Federico and Dasari, Arvind and Hubbard, Joleen and Bekaii-Saab, Tanios and Padukkavidana, Thihan and Hernandez, Luis},
title = {Adverse event costs of systemic therapies for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy and biologics in the US},
journal = {Journal of Comparative Effectiveness Research},
year = {2024},
doi = {10.57264/cer-2024-0084}
}
EUVIMED